Aims Randomized trials showed non-inferior or superior results of the non-vitamin-K-
antagonist oral anticoagulants (NOACs) compared with warfarin. The aim of this study was …

Background: Dronedarone is an amiodarone derivative that was approved in the US in July
2009 to reduce the risk of cardiovascular hospitalization in patients with paroxysmal or …

Abstract Aims Using Scandinavian population-based registries, we assessed risk of
stroke/systemic embolism (SE) and bleeding with non-vitamin K antagonist oral …

Dronedarone is a multichannel blocker with electrophysiologic effects similar to amiodarone.
Dronedarone has been documented to prevent atrial fibrillation recurrences and also has …

The management of patients with atrial fibrillation has changed considerably over the past
decade, largely because of data derived from clinical trials. Although studies comparing …

Background: There are limited data for non-vitamin K antagonist oral anticoagulants
(NOACs) impact on outcomes for patients with atrial fibrillation (AF) and valvular heart …

Aims An important decision in the management of patients with atrial fibrillation is whether to
adopt a rate or rhythm control strategy. Options for the latter include oral membrane-active …

Background No pooled analysis has been undertaken to assess the efficacy and safety of
the non‐vitamin K antagonist oral anticoagulants (NOACs) compared with warfarin in the …

Introduction Outcomes associated with suboptimal use of antithrombotic treatments
(antiplatelets, warfarin, direct oral anticoagulants [DOACs]) are unclear in Chinese patients …

Abstract Aims Oral anticoagulants (OACs) effectively reduce the risk of stroke in atrial
fibrillation (AF). Three non-vitamin K antagonist OACs (NOACs) are introduced in regular …